专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070275938A1 Therapeutic Treatment Methods 失效
标题翻译：治疗方法
公开(公告)号：US20070275938A1
公开(公告)日：2007-11-29
申请号：US11674128
申请日：2007-02-12
申请人： Christopher Reading , Clarence Ahlem , Dominick Auci , Charles Dowding , James Frincke , Mei Li , Theodore Page , Dwight Stickney , Richard Trauger , Steven White
发明人： Christopher Reading , Clarence Ahlem , Dominick Auci , Charles Dowding , James Frincke , Mei Li , Theodore Page , Dwight Stickney , Richard Trauger , Steven White
IPC分类号： A61K31/58 , A61P19/02 , A61K31/56
CPC分类号： A61K31/56 , A61K31/58
摘要： The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.
摘要翻译：本发明涉及化合物用于改善或治疗诸如囊性纤维化，中性粒细胞减少症或其它示例性病症的病症的用途。可以使用的示例性化合物包括3β-羟基-17β-氨基雄甾-5-烯，3β-羟基-16α-氟-17β-氨基雄甾-5-烯，3α-羟基-16α-氟-17β-氨基雄甾-5-烯，3β-羟基-16β-氟-17β-氨基雄甾-5-烯，1α，3β-二羟基-4α-氟代雄甾-5-烯-17-酮，1α，3β，17β-三羟基-4α-氟代雄甾-5-烯，1beta，3β-二羟基-6α-溴代雄甾-5-烯，1α-氟-3β，12α-二羟基雄甾-5-烯-17-酮，1α-氟-3β，4α-二羟基雄甾-5-烯和4α-氟 -3β，6α，17β-三羟基雄甾烷。

2. 发明申请

US20070275937A1 Therapeutic Treatment Methods 有权
公开(公告)号：US20070275937A1
公开(公告)日：2007-11-29
申请号：US11674126
申请日：2007-02-12
申请人： Christopher Reading , Clarence Ahlem , Dominick Auci , Charles Dowding , James Frincke , Mei Li , Theodore Page , Dwight Stickney , Richard Trauger , Steven White
发明人： Christopher Reading , Clarence Ahlem , Dominick Auci , Charles Dowding , James Frincke , Mei Li , Theodore Page , Dwight Stickney , Richard Trauger , Steven White
IPC分类号： A61K31/58 , A61P19/02 , A61K31/56
CPC分类号： A61K31/56 , A61K31/58
摘要： The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.

3. 发明申请

US20070265236A1 Asthma Treatment Methods 审中-公开
标题翻译：哮喘治疗方法
公开(公告)号：US20070265236A1
公开(公告)日：2007-11-15
申请号：US11549825
申请日：2006-10-16
申请人： Christopher Reading , Clarence Ahlem , Dominick Auci , Charles Dowding , James Frincke , Mei Li , Theodore Page , Dwight Stickney , Richard Trauger , Steven White
发明人： Christopher Reading , Clarence Ahlem , Dominick Auci , Charles Dowding , James Frincke , Mei Li , Theodore Page , Dwight Stickney , Richard Trauger , Steven White
IPC分类号： A61K31/56 , A61P11/06
CPC分类号： A61K31/58 , A61K31/56 , Y02A50/411
摘要： The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.
摘要翻译：本发明涉及化合物用于改善或治疗诸如囊性纤维化，中性白细胞减少症或其他示例性病症的病症的用途。可以使用的示例性化合物包括3β-羟基-17β-氨基雄甾-5-烯，3β-羟基-16α-氟-17β-氨基雄甾-5-烯，3α-羟基-16α-氟-17β-氨基雄甾-5-烯，3β-羟基-16β-氟-17β-氨基雄甾-5-烯，1α，3β-二羟基-4α-氟代雄甾-5-烯-17-酮，1α，3β，17β-三羟基-4α-氟代雄甾-5-烯，1beta，3β-二羟基-6α-溴代雄甾-5-烯，1α-氟-3β，12α-二羟基雄甾-5-烯-17-酮，1α-氟-3β，4α-二羟基雄甾-5-烯和4α-氟 -3β，6α，17β-三羟基雄甾烷。

4. 发明申请

US20070213309A1 Sepsis Treatment Methods 失效
标题翻译：脓毒症治疗方法
公开(公告)号：US20070213309A1
公开(公告)日：2007-09-13
申请号：US11549875
申请日：2006-10-16
申请人： Christopher Reading , Clarence Ahlem , Dominick Auci , Charles Dowding , James Frincke , Mei Li , Theodore Page , Dwight Stickney , Richard Trauger , Steven White
发明人： Christopher Reading , Clarence Ahlem , Dominick Auci , Charles Dowding , James Frincke , Mei Li , Theodore Page , Dwight Stickney , Richard Trauger , Steven White
IPC分类号： A61K31/56 , A61K31/58
CPC分类号： A61K31/58 , A61K31/56 , Y02A50/411
摘要： The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3η-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.
摘要翻译：本发明涉及化合物用于改善或治疗诸如囊性纤维化，中性白细胞减少症或其他示例性病症的病症的用途。可以使用的示例性化合物包括3β-羟基-17β-氨基雄甾-5-烯，3β-羟基-16α-氟-17β-氨基雄甾-5-烯，3α-羟基-16α-氟-17β-氨基雄甾-5-烯，3β-羟基-16β-氟-17β-氨基雄甾-5-烯，1α，3β-二羟基-4α-氟代雄甾-5-烯-17-酮，1α，3β，17β-三羟基-4α-氟代雄甾-5-烯，1beta，3β-二羟基-6α-溴代雄甾-5-烯，1α-氟-3β，12α-二羟基雄甾-5-烯-17-酮，1α-氟-3β，4α-二羟基雄甾-5-烯和4α-氟 -3β，6α，17β-三羟基雄甾烷。

5. 发明申请

US20050101581A1 Therapeutic treatment methods 2 审中-公开
标题翻译：治疗方法2
公开(公告)号：US20050101581A1
公开(公告)日：2005-05-12
申请号：US10728400
申请日：2003-12-05
申请人： Christopher Reading , Clarence Ahlem , Dominick Auci , Charles Dowding , James Frincke , Mei Li , Theodore Page , Dwight Stickney , Richard Trauger , Steven White
发明人： Christopher Reading , Clarence Ahlem , Dominick Auci , Charles Dowding , James Frincke , Mei Li , Theodore Page , Dwight Stickney , Richard Trauger , Steven White
IPC分类号： A61K31/56 , A61K31/57
CPC分类号： A61K31/56 , A61K31/58
摘要： The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.
摘要翻译：本发明涉及化合物用于改善或治疗诸如囊性纤维化，中性粒细胞减少症或其它示例性病症的病症的用途。可以使用的示例性化合物包括3β-羟基-17β-氨基雄甾-5-烯，3β-羟基-16α-氟-17β-氨基雄甾-5-烯，3α-羟基-16α-氟-17β-氨基雄甾-5-烯，3β-羟基-16β-氟-17β-氨基雄甾-5-烯，1α，3β-二羟基-4α-氟代雄甾-5-烯-17-酮，1α，3β，17β-三羟基-4α-氟代雄甾-5-烯，1beta，3β-二羟基-6α-溴代雄甾-5-烯，1α-氟-3β，12α-二羟基雄甾-5-烯-17-酮，1α-氟-3β，4α-二羟基雄甾-5-烯和4α-氟 -3β，6α，17β-三羟基雄甾烷。

6. 发明授权

US09499621B2 Felinized antibodies and methods of treating retroviral infections in felines 有权
标题翻译：有害抗体和在猫科动物中治疗逆转录病毒感染的方法
公开(公告)号：US09499621B2
公开(公告)日：2016-11-22
申请号：US14247680
申请日：2014-04-08
申请人： Richard Trauger
发明人： Richard Trauger
IPC分类号： C07K16/00 , C07K16/46 , C07K16/28 , A61K39/395 , A61K45/06
CPC分类号： C07K16/2845 , A61K39/3955 , A61K45/06 , C07K2317/20 , C07K2317/24 , C07K2317/565 , C07K2317/76
摘要： Provided are felinized antibodies and methods for treating or reducing the likelihood of developing a retroviral infection in a feline, decreasing retroviral virion entry into a feline cell, decreasing retroviral virion budding from a feline cell, or decreasing syncytium transmission in a feline. These methods require the administration of at least one felinized antibody or fragment thereof that specifically binds to CD11a and/or CD18, or ICAM-1, and/or decreases or prevents the binding of LFA-1 (CD11a/CD18 heterodimer) to ICAM-1. Also provided are veterinary compositions and methods of identifying candidate agents useful for treating or reducing retroviral infection in a feline, decreasing retroviral virion entry into a feline cell, decreasing retroviral virion budding from a feline cell, or decreasing syncytium transmission in a feline.
摘要翻译：提供了用于治疗或降低在猫科动物中产生逆转录病毒感染的可能性的减毒抗体和方法，减少逆转录病毒病毒体进入猫细胞，减少来自猫细胞的逆转录病毒病毒体出芽，或减少猫科动物中的合胞体传播。这些方法需要给予特异性结合CD11a和/或CD18或ICAM-1的至少一种有丝分裂的抗体或其片段，和/或降低或阻止LFA-1（CD11a / CD18异二聚体）与ICAM- 1。还提供了兽医组合物和鉴定可用于治疗或减少猫科动物中的逆转录病毒感染的候选物质的方法，减少逆转录病毒病毒体进入猫细胞，减少来自猫科动物细胞的逆转录病毒病毒体出芽，或减少猫科动物中的合胞体传播。

7. 发明申请

US20140140997A1 Methods of Treating Retroviral Infections in Felines 审中-公开
标题翻译：治疗猫科动物逆转录病毒感染的方法
公开(公告)号：US20140140997A1
公开(公告)日：2014-05-22
申请号：US14126952
申请日：2012-06-15
申请人： Richard Trauger
发明人： Richard Trauger
IPC分类号： A61K39/395 , A61K31/341 , A61K31/443 , A61K31/366 , A61K31/4525 , A61K31/426 , A61K31/4025 , C07K16/28 , A61K31/427
CPC分类号： A61K39/3955 , A61K31/341 , A61K31/366 , A61K31/4025 , A61K31/426 , A61K31/427 , A61K31/443 , A61K31/4525 , C07K16/2845 , C07K2317/76 , C12N2740/15021
摘要： Provided are methods for treating or reducing the likelihood of developing a retroviral infection in a feline, decreasing retroviral virion entry into a feline cell, decreasing retroviral virion budding from a feline cell, or decreasing syncytium transmission in a feline. These methods require the administration of at least one agent that specifically binds to CD11a and/or CD18, or ICAM-1, and/or decreases or prevents the binding of LFA-1 (CD11a/CD18 heterodimer) to ICAM-1. Also provided are veterinary compositions and methods of identifying candidate agents useful for treating or reducing retroviral infection in a feline, decreasing retroviral virion entry into a feline cell, decreasing retroviral virion budding from a feline cell, or decreasing syncytium transmission in a feline.
摘要翻译：提供了用于治疗或减少在猫科动物中发现逆转录病毒感染的可能性的方法，减少逆转录病毒病毒体进入猫细胞，减少来自猫细胞的逆转录病毒病毒体芽出芽，或减少猫科动物中的合胞体传播。这些方法需要施用至少一种与CD11a和/或CD18或ICAM-1特异性结合的试剂，和/或降低或阻止LFA-1（CD11a / CD18异二聚体）与ICAM-1的结合。还提供了兽医组合物和鉴定可用于治疗或减少猫科动物中的逆转录病毒感染的候选物质的方法，减少逆转录病毒病毒体进入猫细胞，减少来自猫科动物细胞的逆转录病毒病毒体出芽，或减少猫科动物中的合胞体传播。

8. 发明申请

US20150079075A1 Anti-CD11A Antibodies and Uses Thereof 审中-公开
标题翻译：抗CD11A抗体及其用途
公开(公告)号：US20150079075A1
公开(公告)日：2015-03-19
申请号：US14344697
申请日：2012-09-13
申请人： Richard Trauger , Robert Fleischaker
发明人： Richard Trauger , Robert Fleischaker
IPC分类号： C07K16/28
CPC分类号： C07K16/2845 , C07K2317/24 , C07K2317/56 , C07K2317/92
摘要： Provided herein are isolated human, chimeric, and humanized antibodies and antigen-binding fragments thereof that specifically bind to CD11a. Also provided are methods of treating human immunodeficiency virus (e.g., reducing the risk of developing or preventing the development of HIV infection or AIDS) in a subject that has an HIV infection or AIDS that include administering at least one of the antibodies or antigen-binding fragments to the subject. Also provided are methods of crosslinking CD11a on the surface of a cell that include contacting the cell with at least one of the antibodies or antigen-binding fragments. Also provided are compositions (e.g., pharmaceutical compositions) containing at least one of the antibodies or antigen-binding fragments.
摘要翻译：本文提供了与CD11a特异性结合的分离的人，嵌合和人源化抗体及其抗原结合片段。还提供了在具有HIV感染或AIDS的受试者中治疗人类免疫缺陷病毒（例如，降低发展或预防HIV感染或AIDS发展的风险）的方法，包括施用至少一种抗体或抗原结合片段到主题。还提供了在细胞表面上交联CD11a的方法，其包括使细胞与至少一种抗体或抗原结合片段接触。还提供含有至少一种抗体或抗原结合片段的组合物（例如，药物组合物）。

9. 发明申请

US20140348829A1 Felinized Antibodies and Methods of Treating Retroviral Infections in Felines 有权
公开(公告)号：US20140348829A1
公开(公告)日：2014-11-27
申请号：US14247680
申请日：2014-04-08
申请人： Richard Trauger
发明人： Richard Trauger
IPC分类号： C07K16/28 , A61K45/06 , A61K39/395
CPC分类号： C07K16/2845 , A61K39/3955 , A61K45/06 , C07K2317/20 , C07K2317/24 , C07K2317/565 , C07K2317/76
摘要： Provided are felinized antibodies and methods for treating or reducing the likelihood of developing a retroviral infection in a feline, decreasing retroviral virion entry into a feline cell, decreasing retroviral virion budding from a feline cell, or decreasing syncytium transmission in a feline. These methods require the administration of at least one felinized antibody or fragment thereof that specifically binds to CD11a and/or CD18, or ICAM-1, and/or decreases or prevents the binding of LFA-1 (CD11a/CD18 heterodimer) to ICAM-1. Also provided are veterinary compositions and methods of identifying candidate agents useful for treating or reducing retroviral infection in a feline, decreasing retroviral virion entry into a feline cell, decreasing retroviral virion budding from a feline cell, or decreasing syncytium transmission in a feline.
摘要翻译：提供了用于治疗或降低在猫科动物中产生逆转录病毒感染的可能性的减毒抗体和方法，减少逆转录病毒病毒体进入猫细胞，减少来自猫细胞的逆转录病毒病毒体出芽，或减少猫科动物中的合胞体传播。这些方法需要给予特异性结合CD11a和/或CD18或ICAM-1的至少一种有丝分裂的抗体或其片段，和/或降低或阻止LFA-1（CD11a / CD18异二聚体）与ICAM- 1。还提供了兽医组合物和鉴定可用于治疗或减少猫科动物中的逆转录病毒感染的候选物质的方法，减少逆转录病毒病毒体进入猫细胞，减少来自猫科动物细胞的逆转录病毒病毒体出芽，或减少猫科动物中的合胞体传播。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式